Tyra Biosciences Q3 net loss widens to $12.5M; CFO van den Boom to step down, Fuhrman appointed

Tyra Biosciences, Inc.

2022-Q3 EPS reported -$1.02

Net loss of $12.5M in Q3 2022 vs $6.6M a year ago; cash and equivalents $263.2M.
R&D expenses $10.9M (up from $5.5M); G&A expenses $2.7M (up from $1.2M).
CFO Esther van den Boom resigns effective Dec 31, 2022; will provide transitional consulting services.
Alan Fuhrman appointed CFO effective Jan 1, 2023; base salary $440k, target bonus 40%, equity grants.
SURF301 study ongoing; IND for TYRA-200 expected by year-end 2022.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Esther van den Boom

Chief Financial Officer

TYRA · Tyra Biosciences, Inc.

Effective: 2022-12-31
Successor: Alan Fuhrman
Filed: November 3, 2022, 7:59 PM ET

On October 28, 2022, Esther van den Boom, the Chief Financial Officer of Tyra Biosciences, Inc. (the “Company”), informed the Company of her intent to resign as the Company’s Chief Financial Officer, effective December 31, 2022.

Appointed

Alan Fuhrman

Chief Financial Officer

TYRA · Tyra Biosciences, Inc.

Effective: 2023-01-01
Filed: November 3, 2022, 7:59 PM ET

On November 1, 2022, the Board of Directors of the Company (the “Board”) appointed Alan Fuhrman to replace Ms. van den Boom as the Company’s Chief Financial Officer, effective January 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tyra Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income Third quarter 2022 net loss was $12.5 million.

Period: the quarter ended September 30, 2022
Net income: Third quarter 2022 net loss was $12.5 million
Result: reported results

Exact text from the filing

On November 3, 2022, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Esther van den Boom departed as Chief Financial Officer at Tyra Biosciences, Inc..

Action: resign
Role: Chief Financial Officer

Exact text from the filing

On October 28, 2022, Esther van den Boom, the Chief Financial Officer of Tyra Biosciences, Inc. (the “Company”), informed the Company of her intent to resign as the Company’s Chief Financial Officer, effective December 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Alan Fuhrman was appointed as Chief Financial Officer at Tyra Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 1, 2022, the Board of Directors of the Company (the “Board”) appointed Alan Fuhrman to replace Ms. van den Boom as the Company’s Chief Financial Officer, effective January 1, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.